Sionna Therapeutics, INC 8-K filings

Sionna Therapeutics announced topline data from its SION-719 Phase 2a trial did not meet its primary endpoint, leading to the decision not to advance the drug as an add-on therapy, while also providing an update on its SION-451 program.

Sionna Therapeutics reported its Q2 2026 financial results, highlighting that its key clinical trials for SION-719 and SION-451 are on track for topline data this summer, and maintaining a strong cash position expected to fund operations into 2028.

Sionna Therapeutics reported Q1 2026 financial results, highlighting progress in its cystic fibrosis drug development programs with key trial data anticipated in summer 2026 and a strong cash position extending into 2028.

Sionna Therapeutics announced its full-year 2025 financial results and provided updates on its cystic fibrosis pipeline, including anticipated mid-2026 topline data.

Sionna Therapeutics initiated two new clinical trials for its cystic fibrosis drug candidates and reported a strong cash position expected to fund operations into 2028.

Sionna Therapeutics announced positive Phase 1 data for SION-719 and SION-451, maintaining a strong cash position expected to fund operations into 2028, and progressing its cystic fibrosis pipeline.

Sionna Therapeutics, Inc. announced the successful election of three Class I directors and the ratification of Deloitte & Touche LLP as its independent registered public accounting firm at its Annual Meeting of Stockholders held on June 12, 2025.

Sionna Therapeutics reported positive Phase 1 clinical trial results for its NBD1 stabilizers, SION-719 and SION-451, for cystic fibrosis, leading to the advancement of both programs into further clinical development.

Sionna Therapeutics announces completion of Phase 1 dosing for NBD1 stabilizers, a strong cash position following its IPO, and plans to initiate Phase 2a trials, marking significant progress in its cystic fibrosis treatment program.

Sionna Therapeutics announces encouraging Phase 1 data for its CF drug candidates and reports a strong financial position following an upsized IPO.

Sionna Therapeutics completes the filing of its fifth amended and restated certificate of incorporation and amended and restated bylaws following its initial public offering.